Skip to main content

Integra LifeSciences Holdings Corporation

corporate_fare Company Profile

Integra LifeSciences Holdings Corporation

IART·NASDAQ·Industrial Applications And Services·CIK 0000917520

Integra LifeSciences Holdings Corporation is a global medical technology company that manufactures and sells medical technologies and products. The company operates in two reportable business segments: Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT"). The CSS segment accounts for approximately 70% of total revenue and includes market-leading technologies and instruments used in specialties such as neurosurgery, neurocritical care, and otolaryngology (ear, nose, and throat or "ENT"). Integra LifeSciences is a world leader in neurosurgery and one of the top three providers in the U.S. for instruments used in precision, specialty, and general surgical procedures. The TT segment generates about 30% of overall revenue and focuses on wound reconstruction and care, as well as private label products. The company was the first to receive an FDA claim for regeneration of dermal tissue and is a world leader in regenerative technology. They have developed numerous product lines from this technology for applications including burn and deep tissue wounds, repair of dura mater in the brain, and repair of nerves and tendons. Integra LifeSciences has expanded its regenerative technology business to include neurosurgical products, ENT, surgical instruments, and advanced wound care through global acquisitions and product development. Within neurosurgery, the company is a global leader in neuro-access, neuro-surgical, and neuro-monitoring technologies.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 23 items for IART at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Integra LifeSciences Files Shelf Registration for Future Capital Raises
  • Integra LifeSciences Reports Massive $511M Goodwill Impairment, Deep Net Loss Amid Regulatory & Tariff Headwinds
  • Integra LifeSciences Reports Significant FY2025 GAAP Loss Driven by $511M Impairment; Q4 Adjusted EPS Declines, Provides Modest 2026 Guidance

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.64B
Net Income
-$516.47M
Diluted EPS
-$6.74
Op. Cash Flow
$50.38M
Free Cash Flow
-$31.05M
Gross Profit
$831.62M
Operating Income
-$493.37M
Cash & Equivalents
$235.05M
Debt / Equity
0.00×
Net Margin
-31.6%
Shares Outstanding
76.67M sh
Source: 10-K · filed 2026-02-26 · accession 0000917520-26-000011
$12.99 -1.96% today
52-week range · as of 2026-10-21 $8.7 – $20.49
Market cap
$1.03B
Volume
828.6K (0.7× avg)
3-mo avg 1.1M
Live data · 2026-11-22 12:54 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed IART - Filings & News (Page 2)

IART
Feb 26, 2026, 4:59 PM EST
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $11.33
Real-time Price: $12.99 info
Change: +$1.66 (+15%) info
Market Cap: $1.031B info
IART
Feb 26, 2026, 4:02 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $11.33
Real-time Price: $12.99 info
Change: +$1.66 (+15%) info
Market Cap: $1.031B info
IART
Feb 26, 2026, 6:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $11.59
Real-time Price: $12.99 info
Change: +$1.40 (+12%) info
Market Cap: $1.031B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets